Key Studies in NSCLC: Independent Conference Coverage of the 2021 ASCO Scientific Meeting
  • CME

June 4-8, 2021; Online at https://conferences.asco.org/am
Review expert perspectives on the most clinically relevant data on NSCLC presented at the 2021 ASCO Annual Meeting.
Zofia Piotrowska, MD, MHS
Karen L. Reckamp, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 20, 2021 Expiration: August 19, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with lung cancer
  • Identify subpopulations of patients with lung cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with lung cancer
  • Consider how new trial findings might affect treatment of lung cancer clinical practice in the future

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received funds for research support (paid to her institution) from AbbVie, AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, and Tesaro and has received consulting fees from AstraZeneca, Blueprint, C4 Therapeutics, Eli Lilly, Genentech, InCyte, Janssen, Jazz Pharmaceuticals, Medtronic, and Takeda.
Karen L. Reckamp, MD, MS

Professor of Medicine
Director
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Karen L. Reckamp, MD, MS, has disclosed that she has received funds for research support (paid to her institution) from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol Myers Squibb, Calithera, Daiichi Sankyo, Elevation Oncology, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno and consulting fees from Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Calithera, Daiichi Sankyo, EMD Serono, Euclises, Genentech, Guardant, Janssen, Lilly, Merck KGA, Precision Health, Seattle Genetics, Takeda, and Tesaro.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with lung cancer.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 20, 2021, through August 19, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Text module presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 13, 2021 Expired: October 12, 2022

Slideset presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Released: October 13, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue